CenExel iResearch and CenExel ACMR Unveil Dedicated PET Scan Unit for Specialized Research
03. September 2024 09:00 ET
|
CenExel Clinical Research
Atlanta, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- CenExel iResearch and CenExel ACMR, two premier Centers of Excellence located in Atlanta, Georgia, are thrilled to announce the launch of a dedicated...
Curium gibt erste kommerzielle Dosen von PYLCLARI® - 18F-PSMA PET radiopharmazeutikum in Österreich bekannt
17. Juni 2024 08:51 ET
|
Curium
Erste Dosen von PYLCLARI® werden Anfang Mai 2024 in Österreich verabreichtPYLCLARI® jetzt auch in Frankreich, Deutschland, Griechenland, Italien und den Niederlanden erhältlich PARIS, June 17, 2024 ...
Curium Continues to Make Strong Progress in European Roll-Out Of PYLCLARI® – 18F-PSMA PET Diagnostics of Patients With Prostate Cancer
17. Juni 2024 08:51 ET
|
Curium
First doses of PYLCLARI® administered in Austria in early May 2024PYLCLARI® now available in France, Germany, Greece, Italy, and the Netherlands PARIS, June 17, 2024 (GLOBE NEWSWIRE) -- Curium, a...
UK's First National Total-Body PET Imaging Platform Boosts Demand for Expert PET Market Insights
11. Oktober 2023 08:43 ET
|
Research and Markets
Dublin, Oct. 11, 2023 (GLOBE NEWSWIRE) -- As the UK takes a monumental leap towards advanced medical imaging with the unveiling of the National PET Imaging Platform (NPIP), industry professionals,...
Curium Receives Positive CHMP Opinion of PYLCLARI® for Primary Staging of Patients With High-Risk PCa Prior to Initial Curative Therapy and to Localize Recurrence of PCa in Patients With a Suspected Recurrence Based on Increasing Serum Prostate-Specific Antigen (PSA) Levels After Primary Treatment With Curative Intent
26. Mai 2023 03:42 ET
|
Curium
If approved for Europe, PYLCLARI® (INN: Piflufolastat (18F) formerly known as [18F]-DCFPyL) will offer prostate cancer patients access to a diagnostic imaging agent more sensitive than conventional...
Curium Announces Last Patient Enrolled in Their Phase 1/2 SOLAR Clinical Trial Imaging Men with Histologically-Proven Metastatic Prostate Cancer Using Copper Cu 64 PSMA I&T.
23. Mai 2023 12:57 ET
|
Curium
PARIS, May 23, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has completed enrollment in its USA-led SOLAR Phase 1/2 study evaluating the safety,...
2023 United States PET Imaging Market Report: Forecasts to 2026 with Focus on Market Trends in Hospitals and Imaging Centers, Including Procedure Volume, Use of OEM Vs. Third-Party Service Providers and More
06. April 2023 04:18 ET
|
Research and Markets
Dublin, April 06, 2023 (GLOBE NEWSWIRE) -- The "2023 U.S PET Imaging Market Summary Report" report has been added to ResearchAndMarkets.com's offering. This '2023 PET Imaging Market Summary...
Curium Confirms No Supply Challenges in North America and Europe for its Eclipse Phase 3 Clinical Trial
14. März 2023 10:46 ET
|
Curium
To date, an uninterrupted supply of 177Lu-PSMA-I&TRobust supply chains and global transportation infrastructure deliver supply securityCurium’s clinical trials play central role in innovations in...
Germanium-68/ Gallium-68 Generators Market to Reach US$ 140.7 Mn by 2031, TMR Study
13. Dezember 2022 12:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - According to a market report by TMR, the global germanium-68/gallium-68 generators industry...
Global Diagnostic Imaging Services Market Report 2022: Technological Advancements in Diagnostic Imaging to Shape Sector Moving Forward
20. Oktober 2022 04:58 ET
|
Research and Markets
Dublin, Oct. 20, 2022 (GLOBE NEWSWIRE) -- The "Global Diagnostic Imaging Services Market by Procedure (MRI, Ultrasound, CT, X-RAY, Nuclear Imaging, Mammography), Application (OB/Gyn, Pelvic/Abdomen,...